Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...
BioSpace6d
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
pharmaphorum7d
Supernus reports less than super data for depression drug
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
FierceBiotech7d
Options shrink for Supernus depression drug candidate after key trial failure
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
Benzinga.com7d
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with ...
Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...